Proactive Investors - Run By Investors For Investors

Latest data suggests Sareum’s SRA737 Chk1 inhibitor has potential in ovarian cancer

Data presented at a cancer convention in Dublin suggested SRA737 showed “promising efficacy” in pre-clinical models of high-grade serous ovarian cancer
cancer cells
SRA737 is being taken through the clinic by US firm Sierra Oncology

Sareum Holdings Plc’s (LON:SAR) SRA737 checkpoint kinase 1 (Chk1) inhibitor candidate has potential in certain types of ovarian cancer, according to Sierra Oncology, the US firm which has licensed the compound.

Chk1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally caused by chemotherapy or radiotherapy.

READ: Preliminary results from SRA737 clinical trials due in H1 2019

Data presented at a cancer convention in Dublin suggested SRA737 showed “promising efficacy” in pre-clinical models of high-grade serous ovarian cancer (HGSOC).

Sareum said the in vivo – i.e. in a living organism – data support the ongoing phase I/II monotherapy clinical trial of the compound, which is enrolling patients with these HGSOC subtypes.

The AIM company also reckons the data supports the idea that SRA737 could be useful when combined with low-dose gemcitabine – one of the most commonly prescribed chemotherapies – or PARP inhibitors, which stop cancer cells repairing themselves.

Sareum boss “encouraged” by data

An early-stage study of the compound with low-dose gemcitabine is already underway, while Sierra is preparing for a trial which will see SRA737 partnered with niraparib, a PARP inhibitor.

“The data presented today continue to provide evidence that SRA737 has potential in ovarian cancer where the tumours exhibit defective cell cycle checkpoint control and replicative stress, and which is identifiable by genetic markers,” said Sareum chief executive Tim Mitchell.

“This represents a significant proportion of HGSOC patients who currently have few treatment options. We are encouraged by the new data, which supports the rationale for Sierra's clinical study with SRA737 as a monotherapy and look forward to updates from the ongoing clinical trials in the first half of 2019.”

Sareum shares rose 4.8% on the back of the announcement to 0.81p.

View full SAR profile View Profile

Sareum Holdings Plc Timeline

Related Articles

man and woman working in a lab
October 11 2018
There were no adverse safety findings and excellent drug-like properties were confirmed.
eye
November 19 2018
“It’s a blended model of highly cash generative assets and top line growth”
DNA sequence
July 12 2018
The cell therapy specialist also reported there had been industry interest around its main programmes

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use